Boston Scientific Shuffles and Sells in Bid to Right Ship

  
Generate a summary of this article
Listen to this article
Beta

Boston Scientific, in a bid to raise capital and focus its efforts, is selling off lower priority businesses as well as its stakes in nearly 100 private and public companies.

A year ago, Boston Scientific Corp. president and CEO Jim Tobin was outlining his steps to fix its newly acquired prize, Guidant, which he said had been languishing with operational and quality control problems, particularly in its much-prized ICD business. [See Deal] (See "How to Fix a Guidant: Boston Scientific's Tobin Opens Playbook," IN VIVO, December 2006 Also see "How To Fix A Guidant: Boston Scientific's Tobin Opens Playbook" - In Vivo, 1 December, 2006.)

While those clean-up activities are still underway, Boston Scientific management has spent the last few months looking within to find...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

SpotifyApple PodcastsWebsite

More from Business Strategy

Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future

 
• By Edwin Elmhirst and Lucie Ellis-Taitt

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

test carousel

 
• By Saba Afreen

test carousel-In-Vivo

Slow Progress: A Decade Of Cell Therapy In Japan

 
• By Lisa Takagi

After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 
• By Eliza Slawther

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.

More from In Vivo

Vigya test infogram

add a desc test

Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future

 
• By Edwin Elmhirst and Lucie Ellis-Taitt

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

Clone Test Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future - Clone

 
• By Edwin Elmhirst and Lucie Ellis-Taitt

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.